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Immunogenicity and Safety of Seasonal Influenza
Vaccination in Patients with Classic Kaposi’s Sarcoma
Monica Cappelletti1, Adriano Taddeo1, Elena Colombo1, Lucia Brambilla2, Monica Bellinvia2,
Fabrizio Pregliasco3, Maria L. Villa1 and Silvia Della Bella4
Classic Kaposi’s sarcoma (cKS) is a human herpesvirus-8 (HHV-8)-associated lympho-angioproliferative tumor
typically occurring in the elderly. It is associated with HHV-8-driven perturbed balance of peripheral B-cell
subsets, which may have an impact on immune responses to antigenic stimulation. We took advantage of the
common practice of cKS patients to undergo seasonal influenza vaccination because of advanced age and
analyzed the immunogenicity and safety of licensed trivalent influenza vaccine in 46 cKS patients and 44
matched controls. Licensure criteria for immunogenicity were fulfilled in both groups. Four weeks after
vaccination, hemagglutination-inhibition antibody titers against each viral strain contained in the vaccine
increased in patients and controls (all Po0.001). Protection against at least one strain was achieved by 96% of
cKS and 91% of control subjects. Protection against all strains persisted after 12 weeks, demonstrating a long-
lasting response to vaccination. The vaccine was equally well tolerated by patients and controls, as assessed by
evaluating solicited local and systemic reactions to the vaccine, and appearance or increase of antinuclear
autoantibodies. HHV-8 virological rebound was observed in four cKS patients, but was not accompanied by
progression of KS lesions. We conclude that seasonal influenza vaccine given to cKS patients is immunogenic
and safe.
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INTRODUCTION
Kaposi’s sarcoma (KS) is a rare lympho-angioproliferative
tumor of endothelial origin that mainly affects the skin but
may also spread to internal organs. It is grouped into four
epidemiological forms that share identical histological
features but are differentiated on the basis of epidemiological,
clinical, and prognostic criteria: classic (cKS), endemic,
iatrogenic, and AIDS related. Regardless of the clinical
variant, KS is consistently associated with infection by human
herpesvirus-8 (HHV-8), which is the causative agent of this
neoplasm (Mesri et al., 2010). HHV-8 is present in the vast
majority of KS tumor cells (i.e., spindle cells), which are cells
of endothelial origin that undergo typical changes in their
morphology, growth rate, life span, and gene expression
under the effects of HHV-8 infection (Moses et al., 1999;
Ciufo et al., 2001; Wang et al., 2004). HHV-8 is also the
causative agent of certain lymphoproliferative disorders,
according to its ability to establish persistent infection in
the host with tropism for multiple cell lineages. In KS patients,
HHV-8 has been demonstrated to infect a broad range of cell
types, including circulating endothelial progenitor cells
(Della Bella et al., 2008), which represent putative precursors
of spindle cells, and B lymphocytes, which are a major virus
reservoir able to sustain the lytic reactivation and dissemina-
tion of the virus (Monini et al., 1999; Rappocciolo et al.,
2008; Gregory et al., 2009). Because of the dual role played
by B cells in HHV-8 infection, both as virus reservoir and as
agents of humoral immune control, we recently investigated
the impact of HHV-8 infection on B cells in a cohort of cKS
patients and demonstrated indeed that HHV-8 leads to
perturbation of B-cell homeostasis with expansion of subsets
of preimmune B-cell compartment (Della Bella et al., 2010).
To investigate whether the observed B-cell changes may
have an impact on humoral responses to antigenic stimula-
tion, in the present study we assessed the immunogenicity
and safety of licensed influenza vaccination in the same
patients. We took advantage of the common practice of cKS
patients to undergo seasonal influenza vaccination because
of the fact that cKS mainly occurs in the elderly, when
influenza vaccination is recommended, as people aged 65
years and older are at a higher risk of debilitating complica-
tions, hospitalizations, and deaths from influenza (Thompson
et al., 2003, 2004; Varin et al., 2010).
ORIGINAL ARTICLE
2414 Journal of Investigative Dermatology (2012), Volume 132 & 2012 The Society for Investigative Dermatology
Received 27 September 2011; revised 16 March 2012; accepted 22 March
2012; published online 24 May 2012
1Department of Biomedical Sciences and Technologies, University of Milan,
Milano, Italy; 2Institute of Dermatological Sciences, Fondazione IRCCS
Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milano, Italy;
3Department of Public Health, Microbiology and Virology, University of
Milan, Milano, Italy and 4Department of Translational Medicine, University of
Milan, Laboratory of Clinical and Experimental Immunology, IRCCS Istituto
Clinico Humanitas, Rozzano (Milano), Italy
Correspondence: Silvia Della Bella, Department of Translational Medicine,
University of Milan, Laboratory of Clinical and Experimental Immunology,
IRCCS Istituto Clinico Humanitas, via Manzoni 56, Rozzano (Milano), Italy.
E-mail: silvia.dellabella@unimi.it
Abbreviations: ANAs, antinuclear autoantibodies; cKS, classic Kaposi’s
Sarcoma; GMT, geometric mean titer; HAI, hemagglutination inhibition;
HHV-8, human herpesvirus-8
We analyzed hemagglutination-inhibition (HAI) antibody
responses to licensed influenza vaccine in cKS patients and
matched controls. We assessed the safety of vaccine,
including the eventual reactivation of underlying conditions
such as HHV-8 infection and KS lesions. Moreover, because
preimmune B cells bear high autoimmune potential (Varin
et al., 2010), we also investigated whether influenza
vaccination might increase the production of antinuclear
autoantibodies (ANAs) in cKS patients.
RESULTS
Demographics
Forty-six cKS patients and 44 healthy controls were enrolled
into the study. Their demographic characteristics at enroll-
ment are reported in Table 1. KS staging was performed in
accordance with our classification, which takes into account
the prevalent type of lesions, localization, clinical behavior,
evolutive pattern, and the presence of complications
(Brambilla et al., 2003; Della Bella et al., 2006; Taddeo
et al., 2008). All patients were positive for anti-HHV-8
antibody and negative for HIV. Patients in systemic
chemotherapy were excluded. None of the applicants
had acute febrile illness or signs of severe acute illness
at the time of vaccination, a history of anaphylaxis due
to vaccine components, or other inappropriate conditions
to receive vaccination, nor had they suffered from auto-
immune and cancer disease other than KS. All patients
and controls reported receiving influenza vaccine in the
previous year.
B-cell subsets
We reported the count of B-cell subsets in the peripheral
blood of the same cKS patients and controls in a previous
paper (Della Bella et al., 2010). Briefly, the absolute number
of transitional, pre-naı¨ve, naı¨ve, and MZ-like B cells, all
composing the peripheral preimmune compartment, was
significantly higher in cKS patients than in controls (Po0.05
in all cases), whereas the absolute number of B cells of the
antigen-experienced compartment, including IgM-only, iso-
type-switched, and CD27 memory B cells did not change
between patients and controls.
Immunogenicity
Figure 1a shows the proportion of subjects demonstrating
pre-vaccination and post-vaccination seroprotection, con-
ventionally defined as HAI antibody titer X1:40 (EMEA,
1997; FDA, 2007). Before vaccination, the seroprotection
rates against H1N1 and H3N2 strains did not significantly
differ between cKS patients and controls, whereas the
proportion of subjects seroprotected against B strain was
higher among cKS (w2 test: Po0.05). Four weeks after
vaccination, among controls, seroprotection against H1N1,
H3N2, and B strains was achieved in 77%, 82%, and 77% of
the subjects, respectively. The proportion of subjects achiev-
ing seroprotection against each of the viral strains signifi-
cantly increased compared with pre-vaccination. The same
seroprotection rates persisted unchanged 12 weeks after
vaccination. Among cKS patients, 4-week post-vaccination
seroprotection against the three viral strains was achieved
in 87%, 65%, and 83% of the subjects, respectively. The
proportion of subjects achieving seroprotection against each
of the viral strains significantly increased compared with pre-
vaccination. As observed in controls, also in the group of cKS
the same seroprotections rates persisted unchanged 12 weeks
after vaccination. The post-vaccination seroprotection rates
against each viral strain did not significantly differ between
patients and controls, and in both groups they fulfilled the
regulatory criteria for assessing immunogenicity of vaccines
in adult subjects aged over 60 years (EMEA, 1997; FDA,
2007). Overall, protection to at least one viral strain
contained in the vaccine was achieved by 91% of the
healthy controls and 96% of the cKS patients.
Figure 1b shows the proportion of subjects demonstrating
post-vaccination seroconversion, conventionally defined
as either post-vaccination titer X1:40 in pre-vaccination
seronegative subjects or as a minimum 4-fold increase in
post-vaccination titer (EMEA, 1997; FDA, 2007). Four weeks
after vaccination, among controls seroconversion against
H1N1, H3N2, and B strains was achieved in 73%, 68%, and
73% of the subjects, respectively. Among cKS patients,
seroconversion against the three viral strains was achieved in
74%, 43%, and 65% of the subjects, respectively. The sero-
conversion rates against each viral strain did not significantly
differ between patients and controls, and in both groups the
regulatory criteria for assessing immunogenicity of vaccines
Table 1. Baseline characteristics of study participants
Characteristic Healthy controls (n=44)1 cKS patients(n=46)1
Male sex 36 (82) 38 (85)
Age (years) 74±5 74±6
KS stage2
I: Maculo-nodular
A. Slow3 18
B. Rapid4 14
II: Infiltrative
A. Slow3 3
B. Rapid4 6
III: Florid
A. Slow3 1
B. Rapid4 2
IV: Disseminated
A. Slow3 0
B. Rapid4 2
Abbreviation: cKS, classic Kaposi’s sarcoma.
1Data are no. (%) of subjects or mean±SD.
2cKS patients were classified according to our classification that takes into
account the prevalent type of lesions, localization, clinical behavior,
evolutive pattern, and presence of complications (Brambilla et al., 2003).
3Slow evolution.
4Rapid evolution.
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in adult subjects aged over 60 years (EMEA, 1997; FDA,
2007) were fulfilled. As it can be observed in the same figure,
seroconversion to all viral strains persisted 12 weeks after
vaccination in both study groups.
Table 2 reports geometric mean titer (GMT) pre-vaccina-
tion and post-vaccination values and fold increases of HAI
antibody titers in controls and cKS patients. Among healthy
controls, seasonal influenza vaccine led to substantial and
significant 4-week post-vaccination increases in HAI anti-
bodies to the seasonal strains, with an average increase in
the antibody level against H1N1, H3N2, and B strains of
7.5-fold, 6.0-fold, and 15.5-fold, respectively (Wilcoxon
signed-rank test: all Po0.001). Similarly, among cKS patients,
4-week post-vaccination HAI antibody levels against the three
viral strains increased by 9.6-fold, 4.4-fold, and 8.2-fold,
respectively (all Po0.001). As reported in the same table,
significant fold increases of post-vaccination HAI titers
persisted 12 weeks after vaccination in both study groups.
GMT values and fold increases of HAI antibody titers directed
against H1N1 strain were similar in patients and controls. The
immune response to H3N2, although consistent with the
regulatory requirements for the use of vaccine in adults (EMEA,
1997), was lower in cKS patients, with significantly lower
GMT observed 4 and 12 weeks after vaccination in cKS
patients than controls (Mann–Whitney U test: Po0.05 and
Po0.02, respectively). On the contrary, the immune response
to B strain was higher in cKS, with significantly higher GMT
observed at baseline (Po0.05) and 4 weeks after vaccination
(Po0.02). Among cKS patients, no correlation was observed
between immunogenicity parameters (seroprotection rate,
seroconversion rate, GMT, or GMT increase) and either age,
cKS stage, or HHV-8 viremia. No correlation was observed
between pre- and post-vaccination HAI antibodies and any
B-cell subset (data not shown).
Safety
Overall, the vaccine was well tolerated. No serious adverse
event occurred in any study group. Similar frequencies of
solicited local and systemic reactions to vaccine were
reported by cKS patients and controls. Most of the reported
symptoms were considered mild to moderate. The local
reaction most frequently reported by both cKS patients and
controls was pain at the injection site (33% and 36%,
respectively) with or without redness and swelling. Headache
and malaise were the most frequently reported systemic
reactions, reported by 20% and 10% of subjects, respectively.
Mild elevation of body temperature (37.8 1C) was only
reported by one cKS patient 2 days after vaccination.
ANA titers
The percentage of subjects positive for ANAs before
vaccination were similar among cKS patients and controls
(15.2% and 22.7%, respectively; Fisher’s exact tests: P¼NS).
The changes in ANA titers observed in cKS patients and
controls following influenza vaccination are shown in
Figure 2. Among controls, two subjects became positive
(one after 4 weeks and one after 12 weeks). In all but one
subject, positive ANAs persisted 12 weeks after vaccination.
Among patients, five subjects who were initially negative for
ANAs became positive after immunization (four subjects after
4 weeks and one subject after 12 weeks). Moreover, one
control and one patient who were initially positive for ANAs
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Figure 1. Immunogenicity of licensed influenza vaccination. (a) Seroprotection and (b) seroconversion rates against A/Brisbane/59/2007 (H1N1),
A/Brisbane/10/2007 (H3N2), and B/Florida/4/2006 (B) strains were determined by assessing hemagglutination-inhibition (HAI) antibody titers in 44 healthy
controls (white bars) and 46 classic Kaposi’s Sarcoma (cKS) patients (gray bars), before and 4 and 12 weeks after influenza vaccination. *Po0.05, **Po0.01, and
***Po0.001 intra-group 4-week and 12-week post-vaccination versus pre-vaccination; #Po0.05 pre-vaccination cKS versus controls.
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showed an increased titer after vaccination. The post- to pre-
vaccination changes in the level of ANAs did not differ
significantly between cKS and healthy controls. No correla-
tion was observed between pre- and post-vaccination ANA
titers and any B-cell subset, nor between ANA titers and
serological responses to influenza vaccination (data not
shown).
HHV-8 virological rebound
At baseline, five cKS patients (10.9.%) had copy number of
HHV-8 genome above the detection limit of 250 gEq ml1.
The changes in HHV-8 DNA levels observed in cKS patients
after influenza vaccination are shown in Figure 3. Following
influenza vaccination, a virological rebound, defined as an
increase of at least 3-fold from baseline (Hughes et al., 1997;
Kosalaraksa et al., 2011), was observed in one of these
patients and in three cKS patients who had undetectable
HHV-8 DNA before immunization. Virological rebound was
observed 4 weeks after vaccination in two cases and 12
weeks after vaccination in the other two cases. None of the
four patients showing virological rebound experienced a
progression of KS lesions within 12 months starting from
vaccine administration. No correlation was observed be-
tween virological rebound and serological responses to
influenza vaccination (data not shown). Among the four
patients with virological rebound, seroprotection against
H1N1, H3N2, and B strains was achieved by three, two,
and three subjects, respectively; seroconversion was
achieved by three, two, and two patients, respectively, thus
suggesting that immune responses elicited by vaccination in
these subjects do not deviate from responses observed in the
rest of the donors.
Anti-HHV-8 titers
At baseline, all cKS patients had positive anti-HHV-8
antibodies, with observed titers of 1:512 or higher. By
contrast, all healthy controls were HHV-8 seronegative. The
changes in anti-HHV-8 titers observed in cKS patients after
influenza vaccination are shown in Figure 4. Following
vaccination, 11 cKS patients (23.9%) showed an increase of
anti-HHV-8 antibody titer from baseline: three patients
showed a transient increase 4 weeks after vaccination, which
reverted after 12 weeks; two patients showed an increase
after 4 weeks, which persisted 12 weeks after vaccination;
and six patients showed an increase 12 weeks after
vaccination. None of the patients with post- to pre-vaccina-
tion increase of anti-HHV-8 antibodies showed HHV-8
virological rebound. No correlation was observed between
Table 2. Antibody titers against seasonal A/H1N1,
A/H3N2, and B virus before and 4 and 12 weeks after
receipt of seasonal vaccine in cKS patients compared
with healthy controls
Virus, antibody
Healthy controls
(n=44)
cKS patients
(n=46)
A/Brisbane/59/2007 (H1N1)
GMT (fold increase)
Pre-vaccination 28.3 25.5
4 Weeks after vaccination 212.5 (7.5)1 244.0 (9.6)1
12 Weeks after vaccination 113.1 (4.0)1 114.9 (4.5)1
A/Brisbane/10/2007 (H3N2)
GMT (fold increase)
Pre-vaccination 32.1 17.7
4 Weeks after vaccination 193.3 (6.0)1 77.6 (4.4)1,2
12 Weeks after vaccination 106.2 (3.3)1 47.9 (2.7)1,3
B/Florida/4/2006
GMT (fold increase)
Pre-vaccination 11.3 27.92
4 Weeks after vaccination 175.9 (15.5)1 229.7 (8.2)1,3
12 Weeks after vaccination 109.6 (9.7)1 122.0 (4.4)1
Abbreviations: cKS, classic Kaposi’s sarcoma; GMT, geometric mean titer.
1Wilcoxon signed-rank test, for intragroup post-vaccination to pre-
vaccination comparison of GMT: Po0.001.
2Mann–Whitney U test, for inter-groups comparison of GMT: Po0.05.
3Mann–Whitney U test, for inter-groups comparison of GMT: Po0.02.
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Figure 2. Changes in antinuclear autoantibody (ANA) titers after influenza
vaccination. ANAs were monitored in the sera before and after immunization
in 44 healthy controls and 46 classic Kaposi’s Sarcoma (cKS) patients. The
figure shows the number of subjects who became positive (ANA titer X1:80)
or showed an increased ANA titer after vaccination compared with pre-
vaccination; the number of subjects who were positive for ANA before
vaccination and maintained their positive ANA titer unchanged or decreased
after vaccination; the number of subjects who were initially negative for ANA
and persisted negative after vaccination.
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anti-HHV-8 titers and HAI antibody titers in response to
influenza vaccination (data not shown).
DISCUSSION
We recently demonstrated that cKS patients have HHV-8-
driven imbalance in peripheral B-cell subsets, characterized
by an expansion of transitional and other preimmune B cells
(Della Bella et al., 2010). Because of the key role played by
B cells in humoral immunity, in the present study we
investigated whether, in the same patients, perturbation of
B-cell homeostasis might have an impact on humoral
responses to antigenic stimulation. To this aim, we took
advantage of the common practice of cKS patients to undergo
seasonal influenza vaccination because of their advanced
age, and investigated the immunogenicity and safety of
licensed influenza vaccination in these subjects.
We observed indeed that after vaccination seroprotection
to at least one viral strain contained in the vaccine was
achieved by 91% of the healthy controls and 96% of the cKS
patients. A significant increase in HAI titers against the three
viral strains was observed in both patients and controls,
although some differences in antibody levels were observed
between groups. In particular, cKS patients showed lower
post-vaccination GMT values against H3N2 strain and higher
GMT values against B strain than controls. The relevance of
these differences between groups remains difficult to under-
stand because although H3N2 virus infection has been
associated with the highest rates of morbidity and mortality
in the elderly (McBean and Hebert, 2004) cKS immune
responses to H3N2 strain were largely satisfactory. In fact,
according to the European Medicine Evaluation Agency
(EMEA, 1997) criteria for adults X60 years of age, the
immunogenicity after vaccination was adequate in both
patients and controls, achieving after 4 weeks a seroprotec-
tion rate that exceeded 60%, a seroconversion rate that
exceeded 30%, and a GMT fold increase that exceeded 2.0,
for each of all the viral strains. Because influenza vaccination
is usually administered in autumn, although influenza virus
exposures occur well through the end of winter, we measured
HAI titers 3 months after vaccination as well. In both groups,
seroprotection against the three strains persisted unchanged,
demonstrating a lasting response to vaccination, as desirable
(Puthillath et al., 2011), and pointing out that the capacity of
cKS patients to activate antigen-specific humoral responses
was unaffected. This is in contrast with that observed in
subjects with HIV infection, who, similar to cKS patients,
have disrupted balance between peripheral B-cell subsets but
unlike cKS patients show impaired responses to seasonal
influenza vaccination (Fuller et al., 1999; Moir and Fauci,
2009). It is believed that impairment of humoral immunity in
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Figure 3. Changes in human herpesvirus-8 (HHV-8) DNA levels in classic
Kaposi’s Sarcoma (cKS) patients after influenza vaccination. Forty-six cKS
patients underwent measurement of plasmatic HHV-8 DNA before and
after immunization. The Figure shows the number of subjects who after
vaccination presented a virological rebound (defined as an increase of at least
3-fold from pre-vaccination); the number of subjects who had detectable
HHV-8 DNA (i.e., above the detection limit of 250 gEq ml1) before
vaccination and maintained their HHV-8-DNA levels unchanged after
vaccination; and the number of subjects who maintained undetectable
HHV-8-DNA before and after influenza vaccination.
50
46
40
30
N
um
be
r o
f s
ub
jec
ts
20
10
0
41 38
5
Anti-HHV-8 positive, unchanged
Anti-HHV-8 positive, increased
Pre
-va
cci
na
tio
n
4 W
ee
ks
8 W
ee
ks
8
Figure 4. Changes in anti-human herpesvirus-8 (HHV-8) titers after
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antibodies and the number of patients who maintained unchanged
post- to pre-vaccination levels of antibodies are shown.
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those patients may rely mainly on the profound changes
in the quality and number of CD4 T cells caused by HIV
(Cagigi et al., 2010).
In our study, during the influenza season an equal number
of cKS and controls (4 and 4 corresponding to 8.7% and 9.1%
of subjects, respectively) reported influenza-like illness
episodes, defined as temperature X37.8 1C along with cough
or sore throat (Cowling et al., 2010). This observation may
suggest that a similar protection against illness was achieved
in patients and controls. However, because we could not
perform virus isolation owing to the fact that cKS patients
were outpatients coming from all Italian regions, our results
do not strictly demonstrate the clinical efficacy of vaccina-
tion. This is relevant because although seroprotection is
widely used to assess vaccine efficacy and it is still used for
licensing annual update and new vaccines in Europe (EMEA,
1997) the use of post-vaccination titers alone as a surrogate of
vaccine efficacy is at present a matter of debate (McElhaney,
2011; Ohmit et al., 2011). In fact, breakthrough infections
in subjects with high antibody levels have been reported,
especially in the elderly (Govaert et al., 1994), and may
possibly reflect the multifactorial nature of immune protec-
tion against influenza. For instance, antibody responses to
vaccination may fail to detect relevant changes in cellular
immunity.
The rate and intensity of reported solicited local and
systemic reactions to vaccination were similar in patients and
controls and were in accordance with safety outcomes
reported in other studies using virosomal influenza vaccines
(de Bruijn et al., 2005; Evison et al., 2009; Kunzi et al., 2009).
In the suspicion that cKS patients may be more prone to
autoimmunity than controls because of expansion of transi-
tional and other preimmune B cells that are endowed with
high autoimmune potential (Della Bella et al., 2010; Varin
et al., 2010), we measured ANAs in their serum. At baseline,
the frequency of autoantibodies was not increased in the cKS
group, thus confirming our previous results (Della Bella et al.,
2010). Influenza vaccination induced the appearance of new
autoantibodies in a higher, although not significant, propor-
tion of cKS patients (10.9%) than controls (4.5%). Impor-
tantly, newly synthesized autoantibodies after vaccination
had no apparent clinical significance, as no subject among
patients and controls developed clinical signs of overt
autoimmune disease.
Finally, to assess the safety of influenza vaccination in
patients with cKS, we also evaluated vaccination-induced
HHV-8 virological rebound and observed, indeed, an
increase of HHV-8 DNA in four patients (8.7%). Similar
results have been reported in patients with HIV infection
following immunization with influenza or other vaccines
(Staprans et al., 1995; Brichacek et al., 1996; Stanley et al.,
1996; Kosalaraksa et al., 2011). The explanation proposed for
vaccination-induced HIV rebound is that activation of the
immune system, which is a normal response to antigenic
stimulation, may enhance viral replication owing to the
critical role played by cellular activation in the initiation
and propagation of HIV infection (Fauci, 1993). In our
patients, we suggest that immune activation from influenza
vaccination may promote HHV-8 rebound through the
production of inflammatory cytokines, which have been
demonstrated to sustain HHV-8 reactivation (Monini et al.,
1999; Mercader et al., 2000). It is important to note, however,
that in no patient virological rebound was associated with
progression of KS lesions.
In conclusion, in this study we demonstrated that cKS
patients benefit from seasonal influenza vaccination and
achieve the same level of seroprotection and safety as control
subjects, despite bearing B-cell changes secondary to HHV-8
chronic infection. These observations may likely be extended
to all HHV-8 seropositive individuals, unrestricted to the
presence of KS, who reach 70% of adult population in
particular geographical areas (Pfeiffer et al., 2010).
MATERIALS AND METHODS
Study design
This independent clinical study was designed to establish the
effectiveness and safety of seasonal influenza vaccination in patients
with cKS. Forty-six cKS outclinic patients with histologically
confirmed diagnosis of KS were enrolled. Forty-four age- and sex-
matched healthy subjects were enrolled as controls. All subjects
provided written informed consent after the nature and possible
consequences of the study had been explained. The study protocol
was approved by the ethics committee of the Fondazione Istituto di
Ricovero e Cura a Carattere Scientifico Ca’ Granda Ospedale
Maggiore Policlinico. The Declaration of Helsinki Principles was
complied with. In November 2008, all subjects were administered
intramuscularly the licensed 2008–2009 trivalent influenza viro-
somal vaccine (Inflexal; Berna Biotech, Berne, Switzerland) contain-
ing 15 mg hemagglutinin of A/Brisbane/59/2007 (H1N1), A/Brisbane/
10/2007 (H3N2), and B/Florida/4/2006. Blood specimens for serol-
ogical assays were collected from participants immediately before
vaccination and 4 and 12 weeks after vaccination. All serum
specimens were kept at 80 1C until assayed at the same time. All
patients and controls were instructed to record the presence of any
systemic and respiratory symptoms in a symptom diary daily
throughout the entire influenza season.
Immunogenicity assessment
Serum samples were assessed for HAI antibodies to each hemagglu-
tinin of the H1N1, H3N2, and B strains contained in the vaccine,
using a standard microtiter assay, as previously described (Grilli
et al., 1997; Pregliasco et al., 2001). HAI antibody titers that were
below the detection limit (i.e.,o1:10) were assigned a value of 1:5.
The co-primary immunogenicity outcomes were: (a) the proportion
of subjects with antibody titer X1:40 (seroprotection rate); (b) the
proportion of subjects with either a pre-vaccination titer p1:10 and
a post-vaccination titer X1:40 or a pre-vaccination titer X1:40 and
a minimum 4-fold increase in post-vaccination titer (seroconversion
rate); (c) the GMT; and (d) the geometric mean of the within-subject
ratios of pre- and post-vaccination reciprocal antibody titers (GMT
increase).
Safety assessment
At first visit, enrolled subjects were given a diary card containing
a list of solicited adverse events and their grades. On the immuni-
zation day, subjects were observed at the study site for a period of
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30 minutes after vaccination to detect any immediate adverse
reactions. For the next 7 days, subjects were educated to record
the severity of solicited local and systemic adverse events, axillary
temperature, and concomitant medications in the diary card.
Subjects used a standard scale to grade adverse events.
ANA testing
ANAs were monitored in the sera before and after immunization by a
standard indirect immunofluorescence technique on Hep-2 cells
(Virgo ANA-Hep-2 IgG Kit, Hemagen Diagnostics, Columbia, MD).
ANAs titer of 1:80 or higher was considered positive (Manson and
Rahman, 2006).
Determination of plasmatic HHV-8 DNA and anti-HHV-8
antibodies
cKS patients underwent measurement of plasmatic HHV-8 DNA
before vaccination and 4 and 12 weeks after vaccination. HHV-8
DNA was quantified using the HHV-8 Q-PCR Alert Kit (Nanogen
Advanced Diagnostics, Milan, Italy), according to the manufacturer’s
instructions. Results were expressed in genome equivalents (gEq).
The limit of detection was 250 gEq ml1. Anti-HHV-8-specific IgG
antibodies were tested in serum samples using a commercial immu-
nofluorescence assay (HHV-8 IgG IFA, Biotrin, Dublin, Ireland).
Titers of anti-HHV-8 antibodies 1:64 or higher were considered
positive, according to the manufacturer’s instructions.
Statistical analysis
To assess vaccine immunogenicity, pre- and post-vaccination HAI
antibody titers were compared within each group using Wilcoxon
signed-rank tests. For comparison between patients and controls,
differences of HAI antibody titers were tested using the Mann–Whit-
ney U test. Proportions were compared using the w2 tests and Fisher’s
exact tests, as appropriate. Correlations between HAI titers and
B-cell subsets, ANA titers, HHV-8 viral load, and anti-HHV-8 titers
were analyzed using Spearman’s rank test. All analyses were
performed in GraphPad Prism 4.03 (GraphPad Software, San Diego,
CA), using a cutoff of Po.05 for two-tailed tests.
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